Skip to main content
Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: Outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system

Fig. 2

Impact of MRD pre-transplantation and MRD-modified ELN-2022 risk system on clinical outcomes. A Dynastic AUC for overall survival at different time points after transplantation according to ELN-2017, ELN-2022 and MRD-modified ELN-2022 risk system. B Impact of MRD pre-transplantation on overall survival. C Impact of MRD pre-transplantation on cumulative incidence of relapse. D Impact of MRD pre-transplantation combined with ELN-2022 risk stratification on overall survival. E Impact of MRD pre-transplantation combined with ELN-2022 risk stratification on cumulative incidence of relapse. F Relationship of risk groups between ELN-2022 and MRD-modified ELN-2022 risk groups. G Overall survival according to MRD-modified ELN-2022 risk groups. H Cumulative incidence of relapse according to MRD-modified ELN-2022 risk system

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us